GlycoBAR is a startup based in France.
GlycoBAR develops and produces blood group antigen ligands using a proprietary biofermentation process to remove blood group antibodies and enable universal blood products such as plasma and platelets. They supply these antigen ligands and related reagents to medical and industrial customers.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.